Strict Standards: Only variables should be passed by reference in /home/biosuppl/public_html/msm/news/index.php on line 76

Warning: Cannot modify header information - headers already sent by (output started at /home/biosuppl/public_html/msm/news/index.php:76) in /home/biosuppl/public_html/msm/news/FeedWriter.php on line 84
MSM Protein Technologies http://msmprotein.com/news/ MSM Protein Technologies Secures Second Pre-Clinical Debiopharm Milestone http://msmprotein.com/news/msm_protein_technologies_secures_second_preclinical_debiopharm_milestone We are pleased to announce that MSM has satisfied the second pre-clinical milestone in its collaboration with Debiopharm International headquartered in Lausanne, Switzerland. Debiopharm has determined that antibodies generated by MSM have demonstrated the required in vivo efficacy as stipulated in our collaboration agreement and the project has moved into the next phase of development.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company that specializes in discovering antibodies targeting complex cell surface receptors such as G Protein- Coupled Receptors (GPCRs). Using proprietary technologies originating at the Dana Farber Institute and developed within MSM, the company is able to overexpress the cell surface proteins in their native conformation, maximizing the possibility of discovering functional antibodies.

For more information: info@msmprotein.com 781-321-3322

]]>
Wed, 20 Nov 2013 05:00:00 +0000
MSM satisfies first Debiopharm milestone<br> http://msmprotein.com/news/msm_satisfies_first_debiopharm_milestonebr We are pleased to announce that MSM has satisfied the first pre-clinical milestones in its collaboration with Debiopharm of Lausanne Switzerland. Debiopharm has determined that antibodies generated by MSM have satisfied the target molecular profile as stipulated in our collaboration agreement and the project has moved into the next phase of development.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company that specializes in discovering antibodies targeting complex cell surface receptors such as G Protein- Coupled Receptors (GPCRs). Using proprietary technologies originating at the Dana Farber Institute and developed within MSM, the company is able to overexpress the cell surface proteins in their native conformation, maximizing the possibility of discovering functional antibodies.

For more information: info@msmprotein.com 781-321-3322

]]>
Wed, 10 Apr 2013 04:00:00 +0000
MSM is pleased to announce the appointment of Dr. Edward Kislauskis to its Scientific Advisory Board<br> http://msmprotein.com/news/msm_is_pleased_to_announce_the_appointment_of_dr_edward_kislauskis_to_its_scientific_advisory_boardbr MSM is pleased to announce the appointment of Dr. Edward Kislauskis to its Scientific Advisory Board. Dr. Kislauskis is an expert in preclinical research and a recognized thought leader on the topic of animal models of human diseases. He co-founded Biomedical Research Models, Inc. (Worcester), Hygeia Therapeutics, Inc. (Holden), and Endocellutions, Inc. (Marshfield) where he is VP Research. Dr. Kislauskis is also active consultant to a growing number of life science companies. Dr. Albert Zlotnik, the Chairman of the SAB said, "MSM is at a critical juncture where expertise in pre-clinical development is crucial to the company's evolution. Dr. Kislauskis' expertise will prove invaluable to the Company's evolutions from a discovery phase company to a development company.

]]>
Mon, 25 Mar 2013 04:00:00 +0000
Andrea Corcoran appointed as CFO and in-house counsel<br> http://msmprotein.com/news/andrea_corcoran_appointed_as_cfo_and_inhouse_counselbr Andrea Corcoran appointed as CFO and in-house counsel

We welcome Andrea Corcoran as the new Chief Financial Officer and In-House Counsel at MSM. Andrea has an extensive record of applying her expertise in the area of finance and law to the pharmaceutical industry. Most recently, she served as Senior Vice President of Finance at iBio, Inc. Prior to that, she worked as General Council at Tolerx, Inc for 4 years between 2007 and 2011. Likewise, before working at Tolerx she spent 8 years as General Counsel at Idenix Pharmaceuticals, taking the company from a pre-IND, venture-backed enterprise to a public company with a globally approved and marketed drug. Her prior work with early stage bioscience companies will bring invaluable knowledge to MSM.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company that specializes in discovering antibodies targeting complex cell surface receptors such as G Protein- Coupled Receptors (GPCRs). Using proprietary technologies originating at the Dana Farber Institute and developed within MSM, the company is able to overexpress the cell surface proteins in their native conformation, maximizing the possibility of discovering functional antibodies.

For more information: info@msmprotein.com 781-321-3322

]]>
Sat, 03 Nov 2012 04:00:00 +0000
MSM Protein Press Release<br> http://msmprotein.com/news/msm_protein_press_releasebr MSM Protein Technologies announces re-organization and new management and board appointments. (PDF Press Release).

]]>
Thu, 15 Dec 2011 05:00:00 +0000
Anti-G-protein-coupled receptor antibodies successfully generated in collaboration with MSM Protein Technologies (Chiome Press Release)<br> http://msmprotein.com/news/antigproteincoupled_receptor_antibodies_successfully_generated_in_collaboration_with_msm_protein_technologies_chiome_press_releasebr Chiome Bioscience Inc. (Head Office: Ichigaya Tamachi, Shinjuku-ku, Tokyo; President and CEO: Masaaki Fujiwara; hereinafter referred to as “Chiome”) is proud to announce the successful generation of antibodies against a G-protein-coupled receptor (GPCR) in collaboration with MSM Protein Technologies, Inc. (Headquarters: 10 Roessler Road, Woburn, MA 01801, U.S.A., Chairman: Davis Farmer; hereinafter referred to as “MSM”) using, in combination, the Autonomously Diversifying Library (ADLib®) owned by Chiome and the Lesik/Golik Platform, a proprietary technology of MSM.

GPCRs are a family of cell surface receptors that reside within the cell membrane. They are responsible for transmitting signals into and out of the cell and are involved in a host of diseases including cancers, diabetes and many inflammatory conditions. They are attracting many pharmaceutical companies as drug targets. They are the targets for roughly 30% of all small molecule drugs but have proven to be problematic for antibodies because of their size and complexity until recently. The ideal antibody drug would bind at the site where the native signal or ligand binds to the GPCR, thereby blocking or, in some cases, amplifying the signal and modulating the behavior of the cell.

Conventional techniques are not effective in generating antibodies against GPCRs and to date only a handful of functional antibodies have been generated and few have entered clinical development , whereas the successful generation achieved by combining the ADLib® system and MSM’s proprietary technology platform is expected to greatly contribute to the promotion of creating antibody-based drugs, thereby tapping the potential market for anti-GPCR antibodies.

As stated by Masaaki Fujiwara, President of Chiome, “Although GPCRs are important as targets for drugs aimed at the treatment of cancer and immune diseases, it has been said that it is difficult to generate antibodies against GPCRs by conventional techniques. We, in collaboration with MSM, have succeeded in generating anti-GPCR antibodies by a single screening. Thus, we have taken a major step toward the efficient development of promising antibody-based drugs targeting GPCRs. In the future, we will aggressively pursue collaborative research with companies interested in antibody-based drugs targeting GPCRs.”

Davis Farmer, Chairman of MSM, says, “We are very pleased to be able to collaborate with Chiome. We have been delighted with their success in combining our technology for working with GPCRs with the own platform for raising antibodies. We believe the speed and quality of Chiome’s platform holds great promise for creating powerful antibody based therapeutic drugs to these difficult targets.”

ADLib® system The ADLib® system is an innovative antibody generation technology based on homologous recombination activating of chicken DT40 cell. This technology is superior to the conventional technology in some points. For example, this technology can be used to prepare desired antibodies ex vivo in a short time, or approximately 2-3 weeks. In addition, this technology can be used to prepare antibodies against antigens that have been considered difficult until now, because it is able to produce antibodies having theoretically unlimited diversity. Moreover, we succeeded in developing ADLib® axCELL, which can provide antibodies against cell-expressed multiple-trans-membrane proteins at high rates. The ADLib® system could be a world standard technology for monoclonal-antibody production.

Chiome Bioscience Inc. Chiome is a Japanese biotechnology company specializing in the production of antibodies, and development of antibody generating technology, with the ADLib® system, which is an innovative, unique antibody generating platform technology developed at RIKEN. In order to maximize the value of this technology, Chiome will grant partners the non-exclusive license, making great contributions to the development of pharmaceutical and diagnostic agents. For details of Chiome, please visit the following website: http://www.chiome.jp/e/index_e.html. ADLib® is a registered trademark of Chiome Bioscience Inc.

MSM proprietary Technology MSM proprietary technologies, SIMPLTM and the Lesik/Golik platform enable the presentation of multi-spanners such as GPCRs in highly concentrated and purified form while retaining their native conformation and orientation thereby maximizing the probability of raising functional antibodies. MSM has demonstrated the ability to raise functional human antibodies against a number of GPCRs and other membrane proteins.

MSM Protein Technologies, Inc. MSM is closely held drug discovery company based in Boston, MA. MSM is the leader in the display of multi-spanning membrane proteins for antibody drug discovery. MSM was formed in 2005 on the basis of technology originally developed at the Dana Farber Cancer Institute by the company’s founding scientist Dr. Tajib Mirzabekov, and subsequently licensed to MSM. Since then the Company has developed additional, novel technologies that provide greater power and sensitivity to the search for antibody drugs to multi-spanners. For details of MSM, please visit the following website: http://www.msmprotein.com

(Chiome Press Release)

]]>
Mon, 09 May 2011 04:00:00 +0000
MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors<br> http://msmprotein.com/news/msm_protein_technologies_announces_the_appointment_of_dr_christopher_hentschel_to_the_board_of_directorsbr MSM Protein Technologies Announces the Appointment of Dr. Christopher Hentschel to the Board of Directors

Chris Hentschel, PhD., has joined the Board of MSM Protein Technologies. Dr. Hentschel has extensive industry experience. He has served as the original President and CEO of the Malaria Medical Venture (MMV) over the past 10 years, growing the non-profit into a world-class portfolio for the treatment of malaria. Prior to his work at MMV, Chris Hentschel was the Chief Scientific Officer at Centocor before it merged with Johnson and Johnson. Dr. Hentschel was also the founding head of the Collaborative Centre of the UK Medical Research Council in London. His expertise in developing pharmaceutical research projects from start-ups to industry leaders will provide invaluable insight in his role as MSMʼs first outside Director.

About MSM Protein Technologies

MSM Protein Technologies is a closely held drug discovery company based in Medford, MA. The company specializes in discovering fully human, functional antibodies targeting complex cell surface receptors such as GPCRʼs. Using its proprietary SIMPL™ platform and magnetic proteoliposome particles (MPLs), MSM is able to display multispan membrane proteins such as GPCRs in a highly concentrated and purified form while retaining their native conformation and orientation. These technologies, originating at the Dana Farber Cancer institute and developed at MSM, allow the company to maximize the probability of discovering functional antibodies.

For more information: info@msmprotein.com 781-321-3322

]]>
Tue, 25 May 2010 04:00:00 +0000
Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic<br> http://msmprotein.com/news/debiopharm_and_msm_protein_technologies_sign_agreement_for_research_and_development_of_debio_0929_a_novel_oncology_biologicbr Lausanne, Switzerland and Medford, MA, August 20 2009 - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human antibody drug discovery company with world class expertise in targeting multi-spanning membrane proteins, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.

Under the terms of the agreement, Debiopharm and MSM have formed a partnership to select antibodies against the GPCR. Upon completion of the discovery phase, MSM will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody. MSM will retain marketing rights for Russia, Ukraine and several other countries in Eastern Europe and Asia. MSM will receive milestone payments from Debiopharm during the development of the product, as well as a share of royalties on net sales.

“We usually licence-in compounds with existing animal proof of concept, but we were seduced by MSM’s technology and their expertise in the generation of antibodies aimed at GPCRs,” said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. “This is a win-win situation, our companies complement one another. MSMs discovery expertise, together with our experience in drug development should lead to innovative oncology therapeutics.”

“This is a transformational deal for MSM because it represents our first jointly owned program with a global partner. We are pleased to be working with Debiopharm because they are an excellent company that complements MSM’s skill set. We are also happy to be among Debiopharm’s partners in the antibody space,” added Davis Farmer, MSM’s Chairman.

Tajib A. Mirzabekov, Ph.D., President and CEO of MSM commented: “This is a very exciting transaction for MSM. We are working with a great partner, on a very exciting and valuable target and we have the chance to launch what may be the first novel biologic in Russia through our Russian subsidiary, Meprotek. It provides a substantial validation for our technology and our team to work with a company of Debiopharm’s caliber. There is a great need in targeting of GPCRs with functionally active, high quality and potent human monoclonal antibodies.”

About Debiopharm Group Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008. For more information on Debiopharm Group, please visit: www.debiopharm.com.

About MSM Protein Technologies MSM is a closely held drug discovery company based in Boston, MA. MSM is the leader in the discovery of antibodies targeting multispanning membrane proteins. The company applies its proprietary SIMPL ™ platform and magnetic proteoliposome particles (MPLs) to display multispanners such as GPCRs in highly concentrated and purified form while retaining their native conformation and orientation thereby maximizing the probability of raising functional antibodies. MSM has demonstrated the ability to raise functional human antibodies against a number of GPCRs and other membrane proteins. MSM was formed in 2005 on the basis of technology originally developed at the Dana Farber Cancer Institute by the company’s founding scientist and subsequently licensed to MSM. Since then the Company has developed additional, novel technologies that provide greater power and sensitivity to the search for antibody drugs to multispanners. For more information on MSM, please visit: www.msmprotein.com

About G-protein Coupled Receptors (GPCRs) GPCRs comprise a large protein family of transmembrane receptors that sense molecules outside the cell and activate inside signal transduction pathways and, ultimately, cellular responses. A G-protein is an intracellular membrane associated protein, responsible for activating the signalling cascade. GPCRs are coupled to G-proteins. GPCRs are the largest, most versatile group of membrane receptors and also the most pharmaceutically important, as more than 30% of the low-molecular weight drugs currently on the market are targeting this kind of receptors.

]]>
Thu, 20 Aug 2009 04:00:00 +0000
Merck Serono and MSM Protein Technologies Establish Drug Discovery Collaboration Targeted to Complex Cell Surface Receptors<br> http://msmprotein.com/news/merck_serono_and_msm_protein_technologies_establish_drug_discovery_collaboration_targeted_to_complex_cell_surface_receptorsbr http://www.businesswire.com/news/home/20090730005474/en/%20Merck-Serono-MSM-Protein-Technologies-Establish-Drug

]]>
Thu, 30 Jul 2009 04:00:00 +0000
MSM Protein Technologies secures funding from Cystic Fibrosis Foundation<br> http://msmprotein.com/news/msm_protein_technologies_secures_funding_from_cystic_fibrosis_foundationbr http://www.bizjournals.com/boston/blog/mass-high-tech/2008/11/msm-protein-to-make-tool-for-cystic-fibrosis.html

]]>
Mon, 10 Nov 2008 05:00:00 +0000
MSM Protein Technologies Inc. forms drug discovery collaboration with U.K.-based Cambridge Antibody Technology<br> http://msmprotein.com/news/msm_protein_technologies_inc_forms_drug_discovery_collaboration_with_ukbased_cambridge_antibody_technologybr http://www.bizjournals.com/boston/blog/mass-high-tech/2006/10/msm-teams-with-uk-firm-on-drug-discovery.html

]]>
Tue, 17 Oct 2006 04:00:00 +0000